Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 473-477

  Hartmann, Joerg Thomas ^a   Oechsle, Karin ^a   Jäger, Elke ^b   Reis, Hans Edgar ^c   Haag, Cornelie ^d   Niederle, Norbert ^e   Wilke, Hans Joachim ^f   Pflüger, Karl Heinz ^g   Al Batran, Salah ^b   Büchele, Thomas ^h   Hofheinz, Ralf D ⁱ   Kanz, Lothar ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e KLINIKUM LEVERKUSEN   (Germany)

^f KLINIKEN ESSEN MITTE   (Germany)

^g Ev Diakonie Krankenhaus   (Germany)

^h SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Irinotecan; Metastatic colorectal cancer; Phase II; Third line chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG TOLERANCE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TUMOR VOLUME; VOMITING;

EID: 2942576058     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127144.73043.57     Document Type: Article

References (21)

1. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer MetaAnalysis Project. J Clin Oncol 1992; 10:896-903.
3. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52:606-623.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
6. Kohne CH, Van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz M, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22:254 (abstr 1018).
7. Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19:4195-4201.
8. Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 1999; 10:1311-1316.
9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
10. WHO. International Classification of Diseases, 10th edn (ICD-10). Geneva: WHO; 1996.
11. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
12. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
13. Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology 1998; 55:320-35.
14. Jäger E, Klein O, Wächter B, Müller B, Braun U, Knuth A. High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study [Letter]. Eur J Cancer 1995; 31A:1717.
15. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, et al. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 1998; 9:427-431.
16. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomized trial of protracted venous infusion 5- fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8:995-1001.
17. Van Cutsem E, Cunningham D, Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35:54-59.
18. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85:786-795.
19. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
20. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
21. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:129a (abstr 512).